Clobetasol Propionate Foam Recalled for CGMP Deviations
Ingenus Pharmaceuticals is recalling 45,173 cans of Clobetasol Propionate Foam, 0.05%, nationwide due to Current Good Manufacturing Practice (CGMP) deviations. This is a voluntary, FDA Class II recall.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The source text classifies this as FDA Class II and identifies CGMP deviations as the reason for recall. No illnesses, injuries, deaths, or hospitalization reports are mentioned in the source. CGMP deviations constitute a manufacturing/quality issue without confirmed patient harm, qualifying this as a Moderate (score 2) recall.
Plain-English summary
Ingenus Pharmaceuticals, LLC (Orlando, FL) has recalled Clobetasol Propionate Foam, 0.05%, in both 50 g and 100 g cans distributed nationwide in the USA. The recall involves 45,173 cans total across multiple lot numbers with expiration dates ranging from June 2022 through November 2022.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations identified in the manufacturing process. The recall is voluntary and was initiated by the firm.
Consumers and healthcare providers who have this product should stop using it. Patients should consult with their healthcare provider regarding alternative treatment options. The recall was terminated on August 15, 2023.
The recalled product
- Product
- Clobetasol Propionate Foam, 0.05%, packaged in a) 50 g can (NDC 50742-304-50), and b) 100 g can (NDC 50742-304-01), Rx only, Manufactured for: Ingenus Pharmaceuticals, LLC, Orlando, FL 32839-6408.
- Manufacturer
- Ingenus Pharmaceuticals Llc
- Category
- Drug — Topical Corticosteroid
- Hazard
- Affected units
- 45,173
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- a) Lots: 32921 Exp. 06/2022
- 33152 Exp. 08/2022
- 33340 Exp. 11/2022
- b) Lots: 33152 Exp. 08/2022
- 33340 Exp. 11/2022.
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Ingenus Pharmaceuticals Llc
See all →- ModerateFDA Recalls Flunisolide Nasal Solution Due to Out-of-Specification Impurities
FDA (Drugs) · 2022-10-26
- ModerateIngenus Recalls Leucovorin Calcium Injection Due to Crystallization
FDA (Drugs) · 2019-10-23
- LowIngenus Recalls Diclofenac Sodium Topical Solution Due to Leaking Bottles
FDA (Drugs) · 2019-04-03
- SevereIngenus Recalls Irinotecan Hydrochloride Injection Due to Potency Issues
FDA (Drugs) · 2018-07-11
- SevereIngenus Recalls Irinotecan Hydrochloride Injection Due to Potency Issues
FDA (Drugs) · 2018-07-11
Same hazard · cgmp deviation
See all →- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateBaxter Recalls Clindamycin Phosphate Injection Due to CGMP Deviations
FDA (Drugs) · 2026-09-09